Distribution of cell surface glycoprotein CD9 (P24) antigen on megakaryocyte lineage leukemias and cell lines

Imamura, Nobutaka; Mtasiwa, Deodatus M.; Ota, Hiromi; Inada, Tominari; Kuramoto, Atsushi

doi:10.1002/ajh.2830350115

Cited by 8 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to define the location of the plasma membrane more clearly, the cells were treated with an antibody against the CD-9 protein, that is located on the plasma membrane in a number of cell types. 24,33 Immunofluorescence images of LNCaP cells treated with the anti-CD-9 antibody revealed a clear location of the CD-9 protein at the plasma membrane of cells transfected with pCMV-EGFP-TRPL (Fig 3b) and cells transfected with pCMV-EGFP-C1 (Fig 3e). Overlay of the CD-9 and EGFP-TRPL images for each cell transfected with pCMV-EGFP-TRPL showed that the EGFP-TRPL chimeric protein and the CD-9 protein are colocated at the plasma membrane in a band (about 30-50% of the plasma membrane) of the cell (Fig 3c, indicated by the orange color (arrows)).…”

Section: Expression Of the Trpl Protein In Transiently Transfected Lnmentioning

confidence: 99%

See 1 more Smart Citation

Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival

et al. 2003

View full text Add to dashboard Cite

The effects of expression of Drosophila melanoga ster Ca 2+ permeable transient receptor potential-like (TRPL) channels, under the control of the cytomegalovirus (CMV) or prostate cell-specific promoters, on cell survival and apoptosis in the androgen-sensitive LNCaP prostate cancer cell line were investigated. A prostate-specific antigen (PSA) promoter construct (designated PSAEn/PSAPr) composed of a 0.6 kb region of the promoter and a 1.45 kb region of the enhancer resulted in androgen-dependent and prostatespecific expression of a luciferase reporter gene in transiently transfected LNCaP cells. Expression of the enhanced green fluorescence protein-TRPL chimeric protein under the control of the CMV promoter was confirmed by Western blot. Whereas the majority of the expressed protein was located in the cytoplasmic space, confocal microscopy with the CD-9 protein as a plasma membrane marker demonstrated that approximately 10% of the expressed TRPL protein was located in a band in the plasma membrane. Using recombinant adenoviruses, expression of the TRPL protein was associated with an increase in both the initial and sustained rates of Ca 2+ inflow. Expression of TRPL under the control of the CMV promoter for 96 hours decreased cell number and increased the number of cells undergoing apoptosis by 23 and 27%, respectively. Apoptosis was inhibited by a caspase-3 inhibitor, Z-DEVD-fmk. It is concluded that, when heterologously expressed in LNCaP cells, the TRPL protein leads to a reduction in cell survival due, in part, to the induction of apoptosis. The effects of TRPL are likely caused by enhanced Na + and Ca 2+ inflow to the cells. This finding suggests a novel approach to modify the growth of prostate cancer cells that fail to undergo apoptosis following androgen ablation therapy.

show abstract

Section: Expression Of the Trpl Protein In Transiently Transfected Lnmentioning

confidence: 99%

“…24 Briefly, cells were fixed and blocked as described above. Then cells were incubated with 1:40 dilution of anti-CD-9 antibody at 41C overnight and anti-mouse IgG secondary antibody conjugated with Cy3 (1:400 dilution) for 2 h at room temperature.…”

Section: Confocal Microscopymentioning

confidence: 99%

Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival

et al. 2003

View full text Add to dashboard Cite

show abstract

“…On the basis of these findings, the sample was suggestive of acute myeloid leukaemia probably of megakaryoblastic origin. To characterize this type of myeloproliferative disorder accurately, samples from bone marrow were submitted for flow cytometry analysis 1–5 . The immunological panel (Table 2) revealed immunoreactivity for 7.2% CD3 (T lymphocytes), 5.8% CD79 (panB‐lymphocytes), 2.3% CD34 (blast cells), 4.0% CD14 (monocytes), 64.5% CD9 (platelets), 59.5% CD61 (platelets) and 17.7% CD18 (beta2‐integrins).…”

Section: Case Reportmentioning

confidence: 99%

Use of CD9 and CD61 for the characterization of AML‐M7 by flow cytometry in a dog^*

Valentini

Tasca

Gavazza

et al. 2011

Vet Comparative Oncology

View full text Add to dashboard Cite

Acute megakaryoblastic leukaemia (AML-M7) is a rare myeloproliferative disorder in domestic animals. Recently, thanks to the greater availability of immunophenotype techniques, precise diagnosis is more easily made. The morphological evaluation has its limitations, especially in the study of poorly differentiated cells. Few reports have described AML-M7 in dogs using flow cytometry. This clinical case points out the utility of flow cytometry in the characterization of AML-M7 in a 3-year-old German Shepherd dog. Flow cytometry investigation has established megakaryocytic lineage involvement by showing the presence of two megakaryocyte/platelet associated antigens (CD9 and CD61). In human medicine CD9 may be used as a platelet and megakaryocyte marker. There is an evidence of cross-reactivity of human anti-CD9 monoclonal antibody with canine samples. To our knowledge, the use of CD9 has never been described before, for this purpose in the dog.

show abstract

“…CD9 is expressed on a wide variety of cells; within the megakaryocytic lineage CD9 is already expressed during the early stages and therefore can contribute to the diagnosis of AML-M7. 222, 223 For the last antibody position, CD25 was chosen, as some data suggest that this marker is expressed during the early stages of megakaryocytic development. 224 Furthermore, CD25 can be used to detect immunophenotypic aberrant mast cells when a systemic mastocytosis or chronic eosinophilic leukemia (possibly in combination with an AML or MDS) is suspected.…”

Section: Introductionmentioning

confidence: 99%

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

et al. 2012

View full text Add to dashboard Cite

Most consensus leukemia & lymphoma antibody panels consist of lists of markers based on expert opinions, but they have not been validated. Here we present the validated EuroFlow 8-color antibody panels for immunophenotyping of hematological malignancies. The single-tube screening panels and multi-tube classification panels fit into the EuroFlow diagnostic algorithm with entries defined by clinical and laboratory parameters. The panels were constructed in 2–7 sequential design–evaluation–redesign rounds, using novel Infinicyt software tools for multivariate data analysis. Two groups of markers are combined in each 8-color tube: (i) backbone markers to identify distinct cell populations in a sample, and (ii) markers for characterization of specific cell populations. In multi-tube panels, the backbone markers were optimally placed at the same fluorochrome position in every tube, to provide identical multidimensional localization of the target cell population(s). The characterization markers were positioned according to the diagnostic utility of the combined markers. Each proposed antibody combination was tested against reference databases of normal and malignant cells from healthy subjects and WHO-based disease entities, respectively. The EuroFlow studies resulted in validated and flexible 8-color antibody panels for multidimensional identification and characterization of normal and aberrant cells, optimally suited for immunophenotypic screening and classification of hematological malignancies.

show abstract

Distribution of cell surface glycoprotein CD9 (P24) antigen on megakaryocyte lineage leukemias and cell lines

Cited by 8 publications

References 10 publications

Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival

Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival

Use of CD9 and CD61 for the characterization of AML‐M7 by flow cytometry in a dog^*

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

Contact Info

Product

Resources

About

Distribution of cell surface glycoprotein CD9 (P24) antigen on megakaryocyte lineage leukemias and cell lines

Cited by 8 publications

References 10 publications

Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival

Expression of Drosophila Ca2+ permeable transient receptor potential-like channel protein in a prostate cancer cell line decreases cell survival

Use of CD9 and CD61 for the characterization of AML‐M7 by flow cytometry in a dog*

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

Contact Info

Product

Resources

About

Use of CD9 and CD61 for the characterization of AML‐M7 by flow cytometry in a dog^*